M&A Deal Summary |
|
|---|---|
| Date | 2007-12-19 |
| Target | Reliant Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | GSK |
| Sellers(s) | Bay City Capital |
| Deal Type | Add-on Acquisition |
| Deal Value | 1.7B USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1715 |
| Sector | Life Science |
| Employees | 70,212 |
| Revenue | 30.3B GBP (2023) |
GSK is a multinational pharmaceutical, biologics, vaccines and consumer healthcare company. GSK was founded in 1715 and is based in Brentford, United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 9 of 32 |
| Sector (Life Science) | 8 of 26 |
| Type (Add-on Acquisition) | 7 of 24 |
| State (New Jersey) | 2 of 2 |
| Country (United States) | 7 of 19 |
| Year (2007) | 2 of 2 |
| Size (of disclosed) | 9 of 28 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-02-16 |
Praecis Pharmaceuticals
Waltham, Maine, United States Praecis Pharmaceuticals, Inc. is a biopharmaceutical company focused on utilizing its proprietary technologies for the discovery and development of novel compounds that have the potential to address unmet medical needs or improve existing therapies. PRAECIS has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin’s lymphoma and solid tumors, an innovative drug discovery technology, DirectSelect™, which enables the generation and practical use of ultra-large libraries for the discovery of orally active compounds for drug development, and a research and development program aimed at identifying one or more selective S1P-1 agonist compounds to advance into clinical testing. |
Buy | $55M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-04-22 |
Sirtris Pharmaceuticals
Cambridge, Massachusetts, United States Sirtris Pharmaceuticals is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes. Our drug candidates are designed to mimic certain beneficial health effects of calorie restriction by activation of sirtuins, a recently discovered class of enzymes that the Company believes control the ageing process. |
Buy | $720M |
| Category | Venture Capital Firm |
|---|---|
| Founded | 1997 |
| PE ASSETS | 1.3B USD |
| Size | Large |
| Type | Sector Focused |
Bay City Capital LLC was established in 1997 as an equal partnership between The Craves Group and certain Pritzker family business interests for the purpose of managing investment funds in the life sciences industry. Bay City looks for opportunities at all stages of development in biopharmaceuticals, drug discovery, medical devices and diagnostics. Bay City Capital is based in San Francisco, California.
| DEAL STATS | # |
|---|---|
| Overall | 25 of 62 |
| Sector (Life Science) | 16 of 45 |
| Type (Add-on Acquisition) | 12 of 31 |
| State (New Jersey) | 2 of 3 |
| Country (United States) | 23 of 59 |
| Year (2007) | 4 of 4 |
| Size (of disclosed) | 1 of 18 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2007-12-01 |
Aragon Surgical
Palo Alto, California, United States Aragon Surgical, Inc. is a manufacturers of surgical instruments and sterilization container systems. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2008-02-20 |
Cadence Pharmaceuticals
San Diego, California, United States Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. |
Buy | - |
